Cyrano Therapeutics, Inc.
Therapeutic treatments for anosmia and smell loss disorders
- Sector
- Biotech
- Headquarters
- WASHINGTON, DC
- Latest Form D
- $4.1M, Nov 2020
- Total capital
- $4.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $4.1M
- 1 Form D · last Nov 2020
- 71 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 9
- 31 pending · first 2017
- Rank in peer group#179 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$4.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#179 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Richard GeoffrionResearcherExecutive Officer, DirectorLinked by 1 patent
- Robert HenkinResearcherDirectorLinked by 1 patent
- Gerry BrunkDirectorNamed in SEC Form D filings
- Takahide KodaDirectorNamed in SEC Form D filings
What it has protected
USPTO · 9 granted of 40- PendingNasal Spray for Phosphodiesterase InhibitorsUSPTOApplication 19651054
- PendingTreatment Of Chemosensory Dysfunction From A Coronavirus InfectionUSPTOApplication 19533946
- GrantedTreatment of Chemosensory Dysfunction from a Coronavirus InfectionUSPTOUS 12,569,493
Show all 40 patent records
- Nasal Spray for Phosphodiesterase InhibitorsAug 13, 2026 · Application 19651054Pending
- Treatment Of Chemosensory Dysfunction From A Coronavirus InfectionJul 30, 2026 · Application 19533946Pending
- Treatment of Chemosensory Dysfunction from a Coronavirus InfectionMar 10, 2026 · US 12,569,493Granted
- Treatment of Memory Loss with Phosphodiesterase InhibitorsFeb 12, 2026 · Application 19365593Pending
- Methods And Compositions For Diagnosing And Treating Loss And/or Distortion Of Taste Or SmellSep 18, 2025 · Application 19175449Pending
- Phosphodiesterase Inhibitor TreatmentJun 17, 2025 · US 12,329,753Granted
- Methods And Compositions For Diagnosing And Treating Loss And/or Distortion Of Taste Or SmellMay 13, 2025 · US 12,298,316Granted
- Implants for Loss of Taste and SmellJan 9, 2025 · Application 18741915Pending
- Improved Nasal Administration of Pharmaceutical FormulationsDec 26, 2024 · Application 18760127Pending
- Improved Nasal Administration of Parkinson's TherapeuticsDec 26, 2024 · Application 18760128Pending
- Nasal Spray for Phosphodiesterase InhibitorsDec 26, 2024 · Application 18760124Pending
- Gel Treatment for Loss of Taste and SmellDec 5, 2024 · Application 18742344Pending
- Phosphodiesterase Inhibitor TreatmentApr 4, 2024 · Application 18229694Pending
- Methods And Compositions For Diagnosing And Treating Loss And/or Distortion Of Taste Or SmellOct 3, 2023 · US 11,774,458Granted
- Phosphodiesterase Inhibitor TreatmentJul 21, 2022 · Application 17716060Pending
- Compositions And Methods For Treating Chemosensory DysfunctionJul 19, 2022 · US 11,389,453Granted
- Methods And Compositions For Diagnosing And Treating Loss And/or Distortion Of Taste Or SmellSep 21, 2021 · US 11,125,760Granted
- Methods And Compositions For Diagnosing And Treating Loss And/or Distortion Of Taste Or SmellMar 24, 2020 · US 10,598,672Granted
- Phosphodiesterase Inhibitor TreatmentAug 1, 2019 · Application 16103446Pending
- Compostions and Methods for Treating Chemosensory DysfunctionFeb 19, 2019 · US 10,206,927Granted
- Phosphodiesterase Inhibitor TreatmentJan 31, 2019 · Application 15960859Pending
- Methods for Detection of Biological SubstancesMay 24, 2018 · Application 15635979Pending
- Methods For Detection Of Biological SubstancesAug 1, 2017 · US 9,719,988Granted
- Nasal Administration of Parkinson's TherapeuticsApplication 63418663Pending
- Nasal Administration of Parkinson's TherapeuticsApplication 63404227Pending
- Nasal Administration of Pharmaceutical FormulationsApplication 63418662Pending
- Nasal Spray for Phosphodiesterase InhibitorsApplication 63418661Pending
- Nasal Spray for Phosphodiesterase InhibitorsApplication 63297060Pending
- Gel Treatment for Loss of Taste and SmellApplication 63292028Pending
- Implants for Loss of Taste and SmellApplication 63292027Pending
- Gel Treatment for Loss of Taste and SmellApplication 63424584Pending
- Treatment Of Chemosensory Dysfuction From A Coronavirus InfectionApplication PCTUS2021023283Pending
- Treatment of Chemosensory Dysfunction From a Coronavirus InfectionApplication 63006489Pending
- Treatment of Chemosensory Dysfunction From a Coronavirus InfectionApplication 62994172Pending
- Implants For Loss Of Taste And SmellApplication PCTUS2022081622Pending
- Gel Treatment For Loss Of Taste And SmellApplication PCTUS2022081646Pending
- Nasal Spray For Phosphodiesterase InhibitorsApplication PCTUS2023060164Pending
- Improved Nasal Administration Of Parkinson's TherapeuticsApplication PCTUS2023060168Pending
- Improved Nasal Administration Of Pharmaceutical FormulationsApplication PCTUS2023060165Pending
- Treatment of Memory Loss with Phosphodiesterase InhibitorsApplication 63461360Pending
Related companies, and why
- Aurinia Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
- Indi Molecular, Inc.Similar federal contract value in Biotech · null in contracts
- Annovis Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Salarius Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Cellino Biotech IncSimilar federal contract value in Biotech · null in contracts
- Keros TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .